Levels of Interleukin-17 and Interleukin-23 in Patients with Systemic Lupus Erythematosus (SLE) in Trinidad and Tobago
- *Corresponding Author:
- Angel Justiz-Vaillant
Department of Para-Clinical Sciences
Faculty of Medical Sciences
The University of the West Indies
Trinidad and Tobago, West Indies
E-mail: [email protected]
Received date: February 12, 2016; Accepted date: February 27, 2016; Published date: March 03, 2016
Citation: Nobee A, Justiz-Vaillant A, Akpaka PE, Poon-King P (2016) Levels of Interleukin 17 and 23 in Patients with Systemic Lupus Erythematosus (SLE) in Trinidad and Tobago. Immunochem Immunopathol 2:115. doi: 10.4172/2469-9756.1000115
Copyright: © 2016 Nobee A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Serum interleukin (IL)-17 and IL-23 and their association with systemic lupus erythematosus (SLE) is not well understood. A prospective cross sectional and observational study was done using twenty eight (28) SLE patients and fourteen (14) non SLE control subjects. Blood samples were taken to delineate the presence of IL-17 and IL-23 using ELISA among patients of the Rheumatology out-patient clinic at the San Fernando General Hospital, Trinidad and Tobago. The Systemic lupus erythematosus disease activity index (SLEDAI) 2000 score was used for evaluation of activity of the disease. It was found that of all the SLE patients 13 patients (47%) were of Afro-Trinidadian descent, 11 patients (39%) were of Indo-Trinidadian descent and 4 patients (14%) were of mixed descent. The majority of patients were within the 31-35 year age group. Serum IL-17 and IL-23 levels were greater in SLE patients compared to healthy subjects and their levels showed a positive correlation to SLEDAI score. However further experiments are needed to elucidate the role of IL-17 and IL-23 in SLE patients from Trinidad and Tobago.